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Temporal and spatial control of growth factor gradients is critical for tissue patterning and differentiation.
Reinitiation of this developmental program is also required for regeneration of tissues during wound healing
and tissue regeneration. Devising methods for reconstituting growth factor gradients remains a central challenge
in regenerative medicine. In the current study we develop a novel gene therapy approach for temporal and
spatial control of two important growth factors in bone regeneration, vascular endothelial growth factor, and
bone morphogenetic protein 2, which involves application of high intensity focused ultrasound to cells en-
gineered with a heat-activated- and ligand-inducible gene switch. Induction of transgene expression was tightly
localized within cell-scaffold constructs to subvolumes of *30 mm3, and the amplitude and projected area of
transgene expression was tuned by the intensity and duration of ultrasound exposure. Conditions for ultrasound-
activated transgene expression resulted in minimal cytotoxicity and scaffold damage. Localized regions of
growth factor expression also established gradients in signaling activity, suggesting that patterns of growth
factor expression generated by this method will have utility in basic and applied studies on tissue development
and regeneration.
Introduction
Temporally- and spatially restricted patterns ofgrowth factor distribution are critical for the develop-
ment of all tissues. For example, in long bone formation
vascular endothelial growth factor (VEGF) is initially con-
centrated at the margins of the limb anlagen, shifts to the
diaphysis during elongation of the presumptive bone, and at
later times is associated with the hypertrophic zone of
epiphyseal chondrocytes.1 Concentration gradients of bone
morphogenetic proteins (BMPs), including BMPs 2, 4, and
7, also provide essential patterning signals in the develop-
ing limb.2,3 Similar programs of growth factor expression
are also re-initiated during normal fracture healing.4–6 A
major challenge for regenerative medicine is to reconstitute
these developmental patterns of growth factor distribution to
stimulate new tissue formation.
In the area of musculoskeletal tissue regeneration, gene
therapies using BMP-encoding vectors (e.g., plasmids or
viruses) or cells engineered to express BMPs demonstrated
robust healing capacity in animal models of critical-sized
bone defects.7–9 Implantation of cells engineered with
ligand-regulated BMP expression systems also exhibited
osteogenic activity in vivo and additionally afforded tight
temporal control over transgene expression.10,11 However,
methods for achieving combined spatial and temporal con-
trol over the expression of regenerative transgenes have not
been reported, yet may be crucial for localizing the osteo-
genic response and reducing heterotopic ossification and
other systemic toxicities that can arise from uncontrolled
BMP release.12–14
We recently reported on the construction and operation of
a novel synthetic gene switch activated by thermal stress and
dependent on a small molecule ligand (rapamycin, or related
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analogs) to induce transgene expression.15 By using this
gene switch, it was possible to control both the timing and
spatial distribution of VEGF. Exposure to a thermal stress
delivered by a hyperthermic water bath in the presence
of ligand was sufficient to trigger VEGF production
for 5–8 days. Further, cells harboring the gene switch
were readily reactivated in vivo up to a month following
implantation indicating tight and reproducible temporal
control over transgene expression in the targeted ana-
tomical region. Clinical translation of the aforementioned
approach, however, is currently limited in terms of
achieving tight spatial and temporal control of gene ac-
tivation because of an inability to localize the thermal
stimulus.
Focused ultrasound is an emerging clinical technology
primarily used for the thermal and/or mechanical ablation
of cancerous or precancerous tissues deep within the body
(e.g., uterine fibroids and prostate cancer). Using this ap-
proach, ultrasound energy can be focused to small volumes
and generate spatially-restricted regions of hyperthermia. In
current clinical applications, image-guided hyperthermia is
achieved by coupling a magnetic resonance imaging (MRI)
instrument to an integrated high intensity focused ultra-
sound (HIFU) transducer.16,17
Here, we combine the ability of HIFU to spatially control
a thermal stimulus with the heat and ligand-dependent gene
expression system described above to achieve spatial and
temporal control over the production of two important fac-
tors involved in bone development and regeneration, VEGF
and BMP2. It is envisioned that this novel application of
focused ultrasound will provide the spatial and temporal
control over transgene expression necessary to reconstitute
morphogenic signals capable of guiding the regeneration of
bone and other tissues.
Materials and Methods
Gene switch plasmid construction and development
of stable cell lines
Construction and evaluation of heat-activated and rapa-
mycin-dependent gene switches (Fig. 1A) for regulating
firefly luciferase (fLuc) or human VEGF 165 (hVEGF165)
were reported elsewhere.15 C3H10T½-TA clone, stably ex-
pressing the transactivator component of the heat-activated
rapamycin-dependent gene switch was derived from the
multipotent murine progenitor cell line C3H10T½ (ATCC).
The pLH-Z12l-PL-BMP2 vector11 containing the entire
coding sequence of rat BMP2 cDNA was transfected into
C3H10T½-TA cells using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Clones were
selected using hygromycin B (600mg/mL) and screened for
BMP2 secretion 24 h after treatment with 10 nM rapamycin
(LC Laboratories) and subsequent submersion in a 45C
water bath for 30 min. BMP2 secretion was assayed in cell
culture supernatants using a specific ELISA kit (R&D Sys-
tems). A highly inducible clone that exhibited negligible levels
of BMP2 secretion after heat treatment or rapamycin alone
was isolated and termed C3H10T½-BMP2. For propagation
and selection, cells were cultured in a basal medium composed
of high glucose Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen) with 10% (v/v) fetal bovine serum
(FBS; Hyclone), 10 mM HEPES buffer, 100 U/mL penicillin,
100mg/mL streptomycin, and 50mg/mL gentamicin.
Evaluation of heat shock- and ligand-inducible
BMP2 expression in cell-fibrin constructs
C3H10T½-BMP2 cells were evaluated for heat shock-
and ligand-inducible expression of BMP2 using three-
FIG. 1. Development of a heat shock protein (HSP)-based and rapamycin-dependent gene switch for control of BMP2
expression. (a) Gene switch design. The first component of the gene switch comprises a human HSP70B promoter that drives
expression of a bimodular synthetic transactivator (TA). One module contains the FRB rapamycin-binding domain (derived
from human FRAP) and transcriptional activation domains from the p65 subunit of NF-kB and heat shock factor 1 (HSF1). The
second module contains FKBP rapamycin-binding domains and zinc finger homeodomain 1 (ZFHD1) DNA-binding domains.
In the presence of a dimerizer, the TA autoactivates its own expression through ZFHD1 elements and also drives expression of
a transgene of interest [firefly luciferase (fLuc), human VEGF165, BMP2] via the second component of the gene switch. (b)
BMP2 induction requires heat shock and rapamycin/rapalog treatment. C3H10T½-BMP2 cells were suspended in a fibrin
scaffold and exposed to vehicle, 10 nM rapamycin (Rap), and/or a 30 min 45C hyperthermic stimulus as indicated. BMP2 was
measured in the conditioned medium (‘‘medium’’) and lysates (‘‘construct’’) of the cell-scaffold constructs. #p< 0.05 versus
vehicle and 37C controls. Data are mean– standard deviation with n= 4. (c) BMP Responsive Element (BRE) fLuc re-
porter cell assay. Cells were activated as in b except that the rapalog, AP21967 (AP), was used in place of Rap. Conditioned
media were obtained from each condition and added to the BRE luciferase BMP reporter cell line. #p< 0.05 versus vehicle and
37C controls. Data are mean– standard deviation with n= 4. Color images available online at www.liebertpub.com/tec
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dimensional (3D) culture assays. A fibrin scaffold was
chosen for these studies because it is approved for clinical
use in the United States by the Food and Drug Adminis-
tration (FDA), cells can be uniformly distributed throughout
the scaffold, and the mechanical and acoustic properties of
the scaffold can be easily tuned by altering the concentration
of fibrin precursors. To prepare the cell-fibrin constructs, an
appropriate number of cells was first suspended in one
volume of ice-cold 20 U/mL bovine thrombin (Sigma-
Aldrich) dissolved in DMEM. Next, four volumes of ice-
cold DMEM were added to the cell suspension, and finally
five volumes of ice-cold bovine fibrinogen dissolved in
DMEM (20 mg clottable protein/mL; Sigma-Aldrich) were
added to the cell suspension. The fibrinogen solution also
contained 0.1 U/mL bovine lung aprotinin (Sigma-Aldrich)
to limit degradation of the scaffold. After briefly pipetting to
ensure uniform dispersion of the cells, the suspension was
distributed among the wells of 16-well chamber slides (Thermo
Scientific Nunc) at 200mL per well and then warmed to 37C
in a tissue culture incubator for 30 min. The final composition
of the cell-fibrin constructs was 106 cells/mL, 2 U/mL
thrombin, 10 mg clottable protein/mL, and 0.05 U/mL aproti-
nin. Once polymerized, the constructs were removed from the
wells of chamber slides and placed in non tissue culture-
treated 48-well culture dishes (Thermo Scientific Nunc) with
1 mL of basal medium per construct. For reporter assays (see
section, ‘‘Quantification of transgene expression in cell fibrin
constructs’’), the constructs were cultured in a low-serum
(0.1% FBS) variant of the basal medium. Subsets of constructs
were incubated with basal medium containing 10 nM rapa-
mycin or 10 nM AP21967, a nonimmunosuppressive rapa-
mycin analog (‘‘rapalog’’) kindly provided by ARIAD
Pharmaceuticals. Vehicle controls were incubated with me-
dium containing equivalent quantities of carrier solvent (3–
12· 10-4% v/v dimethylacetamide). After incubation with
vehicle or dimerizer for 4 h, the constructs were subjected to a
normothermic or a hyperthermic stimulus by floating the
culture plates containing the constructs on a 37C or 45C
water bath, respectively, for 15–45 min. Following thermal
activation, culture plates were returned to a standard tissue
culture incubator. After 48 h, conditioned media were col-
lected and constructs were minced in five volumes of RIPA
buffer. Construct lysates were centrifuged at 15,000 g for
15 min and the supernatants and conditioned media were as-
sayed for BMP2 uisng a specific ELISA kit (R&D Systems).
The bioactivity of secreted BMP2 was assessed using a
BMP responsive element (BRE) reporter cell line (C3H-B12
cells) kindly provided by Dr D. Logeart-Avramoglou (Paris,
CNRS, France). These cells selectively express fLuc in
response to ng/mL concentrations of BMPs and exhibit
low background levels of fLuc activity when cultured in low
serum-containing media.18 Cells were plated in 24-well cul-
ture dishes at 1.25· 104 cells/cm2 in basal medium containing
10% FBS. The following day, cells were rinsed with serum-
free DMEM and incubated with undiluted conditioned media
collected from induced and noninduced cell-fibrin constructs.
After 1 day of incubation with conditioned media, fLuc ex-
pression was measured by bioluminescence imaging (BLI):
cell membrane-permeable D-luciferin substrate (Promega)
was added to the media at a final concentration of 80mg/mL
and 30 min later the luminescence signal was captured on an
IVIS Spectrum instrument (Perkin-Elmer) in the University
of Michigan Small Animal Imaging Core. Quantitative image
analysis was performed using the proprietary Living Image
software version 4.0 (Perkin-Elmer).
Focused ultrasound-induced hyperthermia
A custom benchtop apparatus was used to deliver focused
ultrasound energy to fibrin scaffolds and cell-fibrin con-
structs (Fig. 2A). The fibrin scaffolds were cast in a six-well
culture dish (Bioflex, Flexcell International) modified to
have acoustically transparent tops and bottoms. The silastic
membrane on the bottom of each well was removed under
aseptic conditions and replaced with a sterile Tegaderm
membrane (3M). Once the scaffolds or constructs were
polymerized within the wells, an autoclaved acrylic annular
platen (Flexcell International) was fit into the top of each
well. The wells were then filled with basal medium with
10 nM rapamycin and sealed with a second Tegaderm
FIG. 2. Application of focused ultrasound to cell-fibrin constructs and induction of localized, mild hyperthermia. (a)
Apparatus for delivering focused ultrasound to cell-fibrin constructs. Circuitry for driving the ultrasound transducer is
shown on the left, including a function generator (Fxn Gen), an RF amplifier (RF Amp), and an impedance matching
network (Z Network). A digital oscilloscope (O-scope) was used to monitor the quality of the driving signal. On the right is
the tank filled with degassed 37C water and a six-well Bioflex dish with fibrin scaffolds or cell-fibrin constructs positioned
near the focus of the transducer. An absorber limits reflection of ultrasound energy into the samples. (b) Time course of
temperature rises within a fibrin scaffold upon exposure to continuous wave ultrasound of ISPTA = 658 W/cm2. Temperature
measurements were made once per second at the indicated distances from the ultrasound focus using a thermocouple. Color
images available online at www.liebertpub.com/tec
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membrane to allow for immersion of the dish in the water
tank. In all cases, the scaffold precursor solutions and cul-
ture media were degassed by vacuum filtration or incubation
under house vacuum immediately prior to placement in the
culture dish.
The Bioflex dish was fixtured perpendicular to the lon-
gitudinal axis of a focused ultrasound transducer in a tank
filled with degassed 37C water. A 2.5 MHz single-element
transducer (H-108; SonicConcepts) with a nominal focal
width of 0.8 mm and axial focal length of 4 mm (both di-
mensions, full width at half maximum) was used for these
studies. The continuous wave driving signal was generated by
an HP3314A function generator (Agilent Technologies) and
amplified by a 55 dB radiofrequency (RF) amplifier (A-300;
ENI). An impedance matching network (SonicConcepts) was
used to improve the efficiency of power delivery to the
transducer, and input waveforms were monitored with an
oscilloscope (LeCroy). The focus of the ultrasound beam was
manually localized within the fibrin scaffold by detecting
abrupt increases in temperature using an implanted thermo-
couple. To accomplish this, a 25G needle (Becton Dickinson)
was fixtured through a sidewall of a well in the culture dish. A
needle-type thermocouple (Hypo-1; Omega Engineering) was
then inserted through the 25G needle and thereby embedded
in the scaffold. Temperatures were recorded using a thermo-
couple data logger (TC-08; Pico Technology) and a laptop
computer running PicoLog data acquisition software (Pico
Technology).
For activation of cells by focused ultrasound, C3H10T½-
fLuc that stably harbors an fLuc reporter gene under con-
trol of the gene switch,15 or C3H10T½-BMP2 cells were
suspended in a fibrin scaffold at 106 cells/mL as described
above. In some experiments, C3H10T½-TA cells were
transiently co-transfected with plasmid pLHZ12-hVEGF165
and pZ12-fLuc15 at a 1:1 molar ratio using Lipofectamine
2000. Cell-fibrin constructs prepared for confocal micros-
copy were doped with 75 mg/mL AlexFluor647-fibrinogen
(Invitrogen). Constructs of 5 mL volume were cast in the
wells of a modified Bioflex dish, allowed to polymerize, and
incubated overnight in basal medium containing 10 nM ra-
pamycin. The Bioflex plate containing the cell-fibrin con-
structs was then immersed in the acoustic exposure tank and
allowed to equilibrate to 37C for ‡ 30 min. The transducer
was positioned to locate the acoustic focus halfway through
the thickness of the cell-fibrin construct. Up to nine ultra-
sound exposures of 5–20 min in duration were performed on
each construct, with each exposure spaced laterally 3–4 mm
apart. The applied acoustic field at the focus for each ex-
posure ranged from a spatial peak time average intensity
(ISPTA) of 658–850 W/cm
2. The corresponding peak com-
pressional and peak rarefactional pressures (PC/PR) for these
intensities were 5.2/-4.2–6.1/-4.7 MPa as measured with a
membrane hydrophone (Reference Shock Wave, Unisyn
Medical Technologies) during preliminary calibration ex-
periments. All exposures were performed at the transducer’s
fundamental frequency of 2.5 MHz, and the resulting pres-
sure waveforms exhibited < 2% total harmonic distortion
over the range of driving voltages used in these studies.
After applying ultrasound, the constructs were asepti-
cally transferred to 60 mm culture dishes with 15 mL basal
medium containing 10 nM rapamycin and incubated over-
night.
Quantification of transgene expression
in cell-fibrin constructs
The expression of fLuc in C3H10T½ -fLuc-populated
constructs was measured by BLI 24 h following exposure to
focused ultrasound essentially as described above. For
evaluation of BMP2 or hVEGF expression in cell-fibrin
constructs, ultrasound-exposed portions of the constructs
were extracted using a 6 mm diameter punch. The extracted
plugs were moved to the wells of a 48-well culture dish with
basal medium containing 10 nM rapamycin and incubated
for 48 h. The quantity of growth factor in conditioned me-
dium and construct lysates was measured by commercially
available ELISAs for BMP2 or hVEGF (R&D Systems).
The bioactivity of BMP2 in ultrasound-exposed C3H10T½-
BMP2-populated constructs was assessed by plating BRE
reporter cells on top of the constructs at 2.5 · 104 cells/cm2
24 h after ultrasound exposure. Co-cultures were then in-
cubated for 48 h in low-serum (0.1% FBS) medium with
10 nM rapamycin and fLuc activity was measured by BLI
following the procedure described above. BRE reporter
activity (as indicated by bioluminescent signal) was cali-
brated against treatment with known concentrations of
rhBMP2 (R&D Systems) in cell monolayers cultured at
similar cell densities and for equivalent durations in 24-well
culture dishes.
Assessment of cell viability and scaffold morphology
The viability of cells encapsulated in fibrin scaffolds
exposed to focused ultrasound was evaluated using the
alamarBlue assay (Invitrogen), which measures cellular re-
ducing activity. Activated regions of C3H10T½-fLuc-
populated constructs were identified by BLI and extracted
using a 6 mm biopsy punch (Miltex). The extracted plugs
were moved to the wells of a 48-well culture dish with
500 mL basal medium containing 10% (v/v) alamarBlue
reagent. Following incubation for 2 h, the conditioned media
were collected and alamarBlue dye reduction was assayed
by measuring fluorescence at lex= 550 nm and lem = 590 nm
on a Gemini Spectramax fluorescence plate reader (Mole-
cular Devices). A subset of extracted plugs from Alexa-
Fluor647-fibrinogen-doped constructs were incubated with
10 mM CellTracker Green (5-chloromethylfluorescein dia-
cetate, CMFDA; Invitrogen) for 1 h in basal medium, rinsed
twice with phosphate buffered saline, and fixed in 4%
paraformaldehyde for 12 h at 4C. After fixation the stained
plugs were mounted in coverwell imaging chambers
(Electron Microscopy Sciences) with PBS and imaged on a
Nikon A1 confocal microscope (Nikon Instruments) with a
10 · objective and 488 and 640 nm diode lasers.
In vivo activation of a heat shock- and ligand-inducible
gene switch with focused ultrasound
All procedures were approved by the University Com-
mittee on the Use and Care of Animals and were in com-
pliance with state and federal laws. In preparation for
implantation of cell-fibrin constructs and subsequent ultra-
sound exposures, the backs of male C3H mice were shaved
and treated with a depilatory cream. C3H10T½-fLuc cells
were suspended in a fibrinogen/DMEM solution and kept on
ice. Immediately prior to injection, the cell suspension was
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mixed with an ice-cold solution of thrombin, rapamycin, and
DMEM. Injections of 500mL/implant were placed lateral to
the spine (one on each side) through a 20G needle (Becton
Dickinson) and allowed to polymerize for 3 h. The final
concentrations of cells, fibrinogen, thrombin, and rapamycin
in each implant were 106/mL, 10 mg/mL, 2 U/mL, and
50 nM, respectively. To apply focused ultrasound to the
implants, mice were anesthesized with isofluorane and im-
mobilized in a 37C water bath such that the lower back of
each animal was submerged. A single element focused ul-
trasound transducer (Sonic Concepts) fit with a water cou-
pling cone was manually aimed at some implants with the
focus positioned within the implant and the longitudinal axis
of the focal volume approximately orthogonal to the skin. A
continuous 2.5 MHz driving signal for the transducer was
generated by an HP3314A function generator and amplified
by a 50 dB RF amplifier (240 L, ENI). Implants were treated
with ISATA = 0 or 658 W/cm2 ultrasound for 10 min. Fol-
lowing application of the ultrasound, mice were returned to
their cages and imaged for bioluminescence the following
day. Briefly, 50 mL of 40 mg/mL D-luciferin substrate in
sterile PBS was injected into each implant and the mice
were immediately placed in the BLI instrument for imaging.
The mice were then returned to their cages and sacrificed the
following day. The implants and overlying skin were re-
sected, fixed in 10% neutral buffered formalin, embedded in
paraffin, sectioned to 5 mm, deparaffinized, and stained with
hematoxylin and eosin. Sections of implants from control
and irradiated regions were then imaged on an Eclipse Ti
microscope (Nikon Instruments) with a 4· objective.
Statistics
Data were analyzed by the general linear model and
Tukey’s post-hoc tests for multiple comparisons using SPSS
version 11.5 (IBM). Spatial profiles of fLuc activity were fit
to 4-parameter Gaussian profiles using IGOR Pro version
5.05A (Wavemetrics). Significant differences between groups
are indicated for p< 0.05.
Results
Characterization of cells engineered
with a heat-activated and ligand-dependent
gene switch to regulate the expression of BMP2
We previously described the development of a heat shock
protein (Hsp)- and ligand-inducible gene switch for strin-
gent control of a luciferase reporter or hVEGF165.
15 Figure
1A summarizes how these gene switches function. Briefly,
the human HSP70B promoter initiates transcription of a
bimodular transactivator (TA). Each module contains a
unique rapamycin-binding domain, and either a DNA-
binding domain or a transcriptional activation domain. The
modules heterodimerize in the presence of rapamycin or the
AP21967 rapalog to form a functional transcription factor.
The chimeric TA thereby drives expression of a transgene of
interest and also activates its own expression through an
autoregulatory loop. Under a regular regimen of dimerizer
administration, the gene switch is able to sustain expression
of the transgene for 5–8 days following a transient (e.g.,
£30 min) heat shock stimulus.15 For applications in carti-
lage and bone regeneration, a stable, clonal cell line was
established containing a gene switch regulating BMP2 ex-
pression. Cells of this line produced nanogram quantities
of BMP2 upon exposure to hyperthermia in the presence
of 10 nM rapamycin (Fig. 1B), yielding concentrations of
BMP2 in the conditioned medium of *4 ng/mL and within
the cell-scaffold construct of *15 ng/mL. Conversely, these
cells exhibited low background levels of BMP2 production
in the absence of thermal stress and/or the dimerizer. These
results demonstrate the tight regulation of BMP2 expression
achievable using this heat shock- and ligand-inducible gene
switch.
A BRE reporter cell line was used to evaluate the bio-
activity of BMP2 in conditioned medium from C3H10T½-
BMP2 cells (Fig. 1C). Significant increases in fLuc activ-
ity were detected in BRE reporter cells treated with condi-
tioned media from C3H10T½-BMP2 cells induced by
heat treatment at 45C for 30–45 min in the presence of
10 nM AP21967 compared with controls not subjected to
hyperthermia and/or exposed to vehicle (Fig. 1C). This
result indicates that induction of the Hsp-based and
dimerizer-dependent cell line results in the secretion of
bioactive BMP2.
Activation of heat-inducible and ligand-dependent
reporter gene expression by focused ultrasound
Induction of cells harboring Hsp-based, rapamycin-
dependent gene switches using nonfocused methods of heat
delivery such as a hyperthermic water bath, leads to global
activation of the monolayer culture or cell-scaffold con-
struct.15 To achieve spatially-restricted patterns of expres-
sion, focused ultrasound was used to control the deposition
of energy within 3D cell-fibrin constructs. The ultrasound
exposure conditions for generating mild hyperthermia
within the constructs were determined using the apparatus
shown in Figure 2A. To calibrate the system, ultrasound was
applied to cell-free fibrin scaffolds and the temperature at
and near the focus of the transducer was measured using an
embedded thermocouple. Figure 2B shows typical temper-
ature rises within a scaffold for an acoustic intensity of
ISPTA = 658 W/cm2. At the focus of the transducer, a maxi-
mumDT &8C was measured after 10 min of ultrasound
exposure, and the peakDT decreased with increasing dis-
tance from the focus. These data demonstrate that focused
ultrasound can generate mild hyperthermia that is restricted
to a millimetric subvolume of a fibrin scaffold.
The next series of experiments measured the ability of
focused ultrasound to activate gene expression in
C3H10T½-fLuc cells suspended in 3D fibrin gels (Fig. 3).
For an acoustic intensity of ISPTA= 754 W/cm2, exposure
times of 5, 10, and 15 min yielded progressive increases in
the projected area and intensity of fLuc activity compared
with nonirradiated regions of the constructs (Fig. 3A, B). In
separate experiments, we found that increases in ultrasound
intensity also yielded significant differences in transgene
expression. For 5 min duration exposures, acoustic intensi-
ties of ISPTA= 658–850 W/cm2 generated significant and
substantial increases in fLuc activity compared with nonir-
radiated regions of the construct (Fig. 3C). In addition, ex-
posures at ISPTA = 850 W/cm2 generated larger areas of
activation compared with exposures at ISPTA = 658 W/cm2
(Fig. 3D). Ultrasound-activated regions of fLuc activity
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FIG. 3. Spatially restricted activation of gene switch activity using focused ultrasound. (a) Time-dependence of induction.
Triplicate fibrin scaffolds containing C3H10T½-fLuc cells were exposed to focused ultrasound (ISPTA = 754 W/cm2) for the
indicated times before measurement of bioluminescence. Scale bar= 5 mm. (b) Quantification of the bioluminescence
signals (average radiance and total flux) in nonirradiated and ultrasound-treated regions of the constructs. #p < 0.05 versus
nonirradiated. Data are mean – standard deviation, n= 3. (c) Ultrasound intensity-dependent activation of C3H10T½-fLuc
cells. Cell-scaffold constructs were exposed to increasing ultrasound intensities for 5 min (ISPTA = 0–850 W/cm2) and the
bioluminescence of treated and nonirradiated regions was quantified 24 h later. #p < 0.05 versus nonirradiated. Data are
mean – standard deviation with n = 6. (d) Ultrasound intensity-dependent increases in the lateral width of fLuc-expressing
region. Mean best-fit Gaussian profiles are shown. $ p < 0.05 for width of 658 W/cm2 versus 850 W/cm2. Dashed line
indicates the geometry of the acoustic beam at the focus. Inset shows typical quality of fit between the measured distribution
of fLuc activity and the best-fit Gaussian profile. (e) A cross section of a cell-fibrin construct treated with three ultrasound
exposures (denoted by three yellow arrowheads; 10 min at ISPTA = 754 W/cm2 for each exposure) focused at different depths
(separated longitudinally by 1.5 mm, laterally by 2 mm) within the construct. The incident surface is on the bottom. Scale
bar = 5 mm.
FIG. 4. Ultrasound-induced expression of bioactive BMP2 in cell-fibrin constructs. (a) Accumulation of BMP2 in condi-
tioned media (‘‘medium’’) and lysates (‘‘construct’’) from cell-fibrin constructs exposed to focused ultrasound (ISPTA= 0–
850 W/cm2). Irradiated and nonirradiated regions of the constructs were extracted following HIFU exposure and cultured
separately. #p< 0.05 versus nonirradiated controls. Data are mean– standard error of the mean with n= 12 for controls and n= 9/
group for ultrasound-treated samples. (b) Schematic describing experimental approach to localizing expression of bioactive
BMP2 following HIFU treatment of C3H10T½-BMP2 cells in a fibrin scaffold. (c) After localization of BRE reporter activity
in cells plated on an ultrasound-treated cell-fibrin construct. Asterisks indicate nominal locations of ultrasound exposure and the
pink dashed line denotes line scan region for quantification. Scale bar= 5 mm. Lower panels indicate quantification of BRE
reporter cell fLuc expression in a line scan across the center of the cell-fibrin construct and a calibration curve showing the
relationship between BRE reporter cell fLuc expression and treatment with known concentrations of rhBMP2.
774
were found to be restricted along the longitudinal axis of the
acoustic beam. By moving the transducer along the longi-
tudinal axis, targeted activation in the third dimension was
observed (Fig. 3E). These results indicate that focused ul-
trasound can activate cells engineered with a heat- and
ligand-inducible gene switch in a highly spatially restricted
manner. In addition, the magnitude and area of activation
may be tuned by the duration and intensity of ultrasound
energy delivered at the focus.
Spatially controlled induction of regenerative
transgenes using focused ultrasound
To determine whether focused ultrasound could be used
to activate expression of a regenerative transgene within a
defined spatial volume, cell-fibrin constructs containing
C3H10T½-BMP2 cells were examined. Following exposure
to HIFU, irradiated and nonirradiated regions were extracted
and cultured separately. Irradiated regions of constructs ex-
hibited significant, intensity-dependent increases in BMP2
measured in conditioned medium and lysates compared
with nonirradiated regions of the same construct (Fig. 4A).
Similar results were obtained after ultrasound activation of
cells harboring a gene switch regulating the expression of
hVEGF165 (Supplementary Fig. 1; Supplementary Data are
available online at www.liebertpub.com/tec), with elevated
levels of hVEGF detected up to 96 h after irradiation. This is
consistent with our previous data describing the dose de-
pendence and kinetics of transgene overexpression follow-
ing a generalized hyperthermic stimulus.19 To further define
the degree to which BMP2 synthesis was spatially restricted
within constructs, BRE-reporter cells were plated on a cell-
fibrin construct previously irradiated with focused ultra-
sound and the pattern of reporter luciferase activity was
imaged (experimental approach shown schematically in
Fig. 4B). As shown in Figure 4C (upper panel), the BMP2
produced by ultrasound-activated C3H10T½-BMP2 cells
was able to generate a highly spatially restricted pattern of
BMP signaling. Image analysis revealed that elevated
BRE reporter activity dissipated laterally to background
levels within 3 mm of the ultrasound focus (Fig. 4C, lower
left panel). Based on prior experiments where BRE re-
porter activity was calibrated against known concentrations
of rhBMP2 (Fig. 4C, lower right panel), apparent local
concentrations of bioactive BMP2 produced by ultrasound-
activated C3H10T½-BMP2 cells were in the range of 1–
5 ng/mL.
Cell viability and scaffold morphology
in ultrasound-irradiated cell-fibrin constructs
Quantitative metabolic assays were used to measure cy-
totoxic effects of the ultrasound exposures on cells sus-
pended in a fibrin scaffold. No significant differences in
metabolic activity were detected for exposure times of 5–
15 min at an acoustic intensity of ISPTA = 754 W/cm2 com-
pared with nonirradiated regions of the construct (Fig. 5A).
Similarly, no substantial differences in metabolic activity
were detected for acoustic intensities of ISPTA=658–850 W/cm2
and an exposure time of 5 min, although a modest ( < 7%),
but significant, reduction in metabolic activity was detected
for ISPTA= 754 W/cm2 in this experiment (Fig. 5B). These
results suggest that the ultrasound exposure times and in-
tensities required to activate cells harboring the heat- and
ligand-inducible gene switch had limited cytoxicity.
Confocal microscopy analysis of the cell-fibrin constructs
provided insight into localized effects of the focused ultra-
sound on the cells and scaffold. At the incident surface of
the constructs, regions devoid of viable cells were detected
and the area of these regions increased with the intensity of
the applied ultrasound (Fig. 5C, left panels). In addition to
clearance of viable cells, increases in the density of fluor-
escently tagged fibrinogen—indicative of consolidation of
the scaffold—were noted within the focal regions. At short
distances distal to the incident surface, however, these ef-
fects on the cells and the scaffold were diminished (Fig. 5C,
right panels). For example, at an acoustic intensity ISPTA =
658 W/cm2, the density of viable cells was comparable to
that of nonirradiated regions of the construct just 80 mm
(*2% of the typical axial dimension of gene activation)
distal to the incident surface. Higher intensity ultrasound
exposures (ISPTA= 754 or 850 W/cm2) led to wider and
deeper-penetrating regions of cell clearance and scaffold
consolidation. In summary, application of focused ultra-
sound at energies capable of inducing transgene expression
had only minor effects on cell viability.
To evaluate the in vivo response of cells engineered with
a heat- and ligand-inducible gene switch, focused ultra-
sound was applied to subcutaneous implants composed of
C3H10T½-fLuc cells in a fibrin scaffold. Twenty-four hours
after application of ultrasound, substantial increases fLuc
expression was observed in the irradiated region, whereas
very little bioluminescent signal was observed in nonirra-
diated control implants (Fig. 6A). Histologic sections of
control and ultrasound-treated implants revealed little dif-
ference in cell or tissue morphology, indicating that the
acoustic energy did not incur damage to the implant and
tissues near the focus (Fig. 6B). These results demonstrate
the potential for focused ultrasound to selectively activate
heat shock- and ligand-inducible gene switches in vivo.
However, considerable optimization of ultrasound dosing
and duration will be required before in vivo studies can be
initiated to control the formation of vasculature or bone.
Discussion
BMPs have demonstrated efficacy in stimulating bone
formation in animal models and human clinical applica-
tions, but the supraphysiologic doses of recombinant pro-
tein required are associated with systemic side effects such
as inflammation, heterotopic ossification, and, in some cases,
cancer.14 Advanced materials for controlling the release
of regenerative growth factors show some promise in pro-
longing and localizing BMP activity to improve bone
healing,20–22 but these platforms are generally limited to first-
order release kinetics that preclude reconstitution of more
complex kinetic profiles such as those that occur during de-
velopment. Here, we demonstrate a method of actively regu-
lating the release of regenerativegrowthfactors inboth timeand
space through the targeted application of focused ultrasound to
cell-fibrin constructs engineered with a ligand-dependent, heat-
inducible gene expression system. Regions of transgene ex-
pression as small as* 30 mm3 were measured in our studies,
and the amplitude and volume of transgene expression could be
tuned by the acoustic intensity or exposure time.
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Both nonfocused and focused ultrasound have been pre-
viously used to activate expression of Hsp-based gene ex-
pression systems.19,23,24 These studies demonstrated the
potential for ultrasound to activate the heat shock pathway
and to target the overexpression of either a reporter gene
such as fLuc or a cytotoxic transgene such as Fas ligand under
the direct control of HSP70 gene promoters. We adapted
this approach for use with a dual requirement gene expres-
sion system that provides durable expression of regenera-
tive transgenes such as BMP2 and hVEGF165. In contrast to
systems exclusively controlled by HSP promoters, the heat-
activated and ligand-dependent gene switch is engineered to
avoid inadvertent activation and provide sustained expression
of the transgene (i.e., >1–2 days), which is important for
growth factor-stimulated bone or cartilage formation. This is
also the first study to demonstrate the use of focused ultra-
sound to stimulate temporal control over regenerative factor
synthesis in engineered tissues.
The acoustic intensities and exposure times required to
activate transgene expression in cells suspended in the fibrin
FIG. 6. In vivo activation of heat
shock- and ligand-inducible gene
switch activity with focused ultra-
sound. (a) Bioluminescence imaging
of a representative animal with control
(encircled by pink dashed line) and
ultrasound-irradiated (ISATA = 658
W/cm2 for 10 min; asterisk) cell-fibrin
subcutaneous implants. Image was
captured 24 h following ultrasound
exposure. Scale bar= 10 mm. (b) He-
matoxylin and eosin staining of his-
tologic sections of subcutaneous
implants following ultrasound expo-
sure. Dashed line indicates implant–
skin interface. Scale bars = 50 mm.
FIG. 5. Viability and morphology of cell-fibrin constructs exposed to focused ultrasound. (a) Metabolic activity of
portions of cell-fibrin constructs treated with focused ultrasound for increasing times (0–15 min., ISPTA = 754 W/cm2). No
differences in metabolic activity measured using an alamarBlue dye reduction assay were detected. Data are
mean – standard deviation with n = 9 for controls and n = 3/group for ultrasound-treated samples and are expressed as
percent control fluorescence of cells not exposed to ultrasound. (b) Metabolic activity of cell-fibrin constructs treated for
5 min with increasing ultrasound intensities (ISPTA = 0–850 W/cm2). #p < 0.05 versus nonirradiated controls. Data are
mean – standard deviation with n = 9 for controls and n = 6/group for ultrasound-treated samples. (c) Confocal microscopic
images of viable cells (labeled with CMFDA, green) and fibrin scaffold morphology (labeled with AlexaFluor647-fibrin-
ogen, AF647-Fbgn, red) in control and ultrasound-treated regions (10 min, ISPTA = 0–850 W/cm2) of cell-fibrin constructs.
Left images captured at the surface of the construct incident to the acoustic beam. Right images captured 80mm distal from
the incident surface. Scale bar= 250 mm. Color images available online at www.liebertpub.com/tec
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scaffold are rather high relative to those used in typical
imaging instruments, but low compared with other thera-
peutic ultrasound modalities. The maximum mechanical
index (MI, an indicator for the potential of ultrasound to
induce cavitation; defined as PR/Ofrequency) permitted by
the FDA for ultrasound imaging instruments is 1.5, the
range of mechanical indices used in the current study was
2.7–3.0. The FDA does, however, permit the application of
higher MI ultrasound energies for therapeutic purposes
(e.g., MRI-guided HIFU ablation procedures) and we found
no evidence of cavitation, such as homogenization of the
cell-scaffold construct, in our experiments. The examined
intensities bracketed the minimum required to trigger
transgene expression and the maximum allowable without
perforating the Tegaderm membranes used in the experi-
mental setup. Although ultrasound exposures of ISPTA=
658 W/cm2 did not trigger substantial cytotoxicity or
damage to the fibrin scaffold, some clearance of viable cells
and consolidation of the fibrin scaffold at the incident sur-
face was observed. Acoustic radiation force or fluid
streaming may be responsible for such effects.25,26 Speed of
sound measurements indicated that the acoustic attenuation
of the fibrin scaffold is very low, *0.05 dB/cm/MHz or 5–
10% of the attenuation of soft tissue,27 indicating that much
of the ultrasound energy passes through the constructs
without being absorbed or scattered and converted to heat.
In unpublished studies, we found that increasing the density
of the fibrin scaffold by adding bovine serum albumin, in-
soluble elastin particles, or more clottable protein increased
the attenuation by 2–10-fold, suggesting that the scaffold
can be modified to attenuate more of the ultrasound energy.
Studies are currently underway to identify combinations of
higher attenuating scaffolds and lower intensity acoustic
exposures that provide robust activation of transgene ex-
pression and reduce adverse effects on cell viability and
scaffold morphology. Tuning the acoustic beam geometry,
frequency, and delivery mode (continuous vs. pulsed) are
alternative approaches to improving energy deposition and
minimizing adverse effects within the cell-scaffold constructs.
The use of rapamycin as a dimerizing agent could po-
tentially interfere with processes such as proliferation re-
quired for regeneration. This naturally derived compound
acts as an inhibitor of the mammalian target of rapamycin
pathway that regulates many growth-related processes. In-
deed, rapamycin inhibits the proliferation and differentiation
of a preosteoblast cell line and primary bone marrow-
derived stromal cells.28 Previous studies in our lab, however,
have shown that the doses of rapamycin required for activa-
tion of rapamycin-dependent gene switches do not block bone
formation in vivo.11 In addition, nonimmunosuppresive syn-
thetic analogs of rapamycin, such as AP21967, retain high
affinity for the FRB and FKBP domains found in transacti-
vator modules and thus can serve as reliable dimerizing
agents29 that exhibit much lower anti-proliferative activity
than rapamycin.30
Although the heat-activated gene switches described in
our study used rapamycin/rapamycin analogues as activat-
ing ligand, this system can be adapted to the use of different
ligands, thereby providing control over a range of regener-
ative factors. For example, we previously described a mif-
epristone-dependent heat shock-inducible gene switch31 that
could be adapted for ultrasound-mediated regulation of an
additional osteogenic factor, such as fibroblast growth factor
2 or parathyroid hormone, which would augment the re-
generative effects of VEGF or BMP2. Previous attempts at
combining delivery of growth factors have yielded modestly
improved, but ultimately disappointing results compared with
monotherapies in animal models of bone healing.19,32–35
With advanced methods of regulating the timing and lo-
calization of transgene expression, combination therapies
may prove substantially more effective than single growth
factor treatments for applications in regenerative medicine.
Stable cell lines harboring the heat shock-inducible and
ligand-dependent gene switches were used in the current
studies for convenience and consistency, but translation of
this technology to the clinic will require reliable methods
for efficient gene transfer to target cell populations (e.g.,
autologous progenitor cells). Nonviral methods such as
nucleofection, an electroporation-based gene transfer tech-
nique, has been used to deliver plasmids encoding BMPs
into human mesenchymal progenitor cells with moderate
success.36 Viral vectors are currently the most efficient
means of delivering transgenes into cells, but often
carry risk of immunogenicity and transformation of infected
cells. AAV, in contrast, are not pathogenic or immunogenic
and neither recombinant AAV (rAAV) nor its parental vi-
rus has been shown to induce malignancies in humans.
These features, combined with the stability of the trans-
genic expression provided by rAAV and their ability to
transduce a variety of cells confer exceptional value to this
biological tool in gene therapies intended to promote tissue
regeneration.37–39
The results of our in vivo study provide proof of principle
that ultrasound can be safely used to target and activate gene
switch-engineered cells placed within the body. However,
induction of bone or vasculature will require the identifi-
cation of optimal conditions for stimulating BMP or VEGF
expression in vivo. In addition, clinical grade image-guided
ultrasound instruments will be required to tightly control the
deposition of acoustic energy into implanted cell-scaffold
grafts. Magnetic resonance thermography is the most com-
monly used method of imaging ultrasound-generated hy-
perthermia within the body, and provides real-time control
over the deposition of acoustic energy based on a target
temperature for a target volume of tissue. Therefore, many
of the tools are in place to implement an ultrasound-acti-
vated cell-based therapy for the regeneration of large tissue
defects.
Conclusions
This study demonstrates that focused ultrasound can acti-
vate cells harboring a heat activated- and ligand-dependent
gene switch to induce the expression of a regenerative growth
factor within a precisely defined 3D space. Ultrasound had
limited cytotoxicity on targeted cells within scaffolds and
induced only minor structural damage to the hydrogel scaf-
fold. This approach to controlling the spatial and temporal
patterns of growth factor expression should have broad utility
in basic and applied studies of tissue regeneration.
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